검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Autologous immune Cells (Autologous immune Cells) Liaoning Medical Diagnosis and Tre…·Lung Cancer (Locally Advanced or M… 31 trials |
|---|---|
Overview Program | Autologous immune Cells |
Overview Company | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. |
Overview Modality | CGT |
Overview Target | Lung Cancer (Locally Advanced or Metasta |
Overview Indication | Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | checkpoint co-expression score correlated with both overall and contact-dependent tumor cell death |
MoA Biomarker | biomarkers and therapeutic targets for investigating tumor-specific immune responses following locoregional t |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Autologous tumor-immune effusion cocultures enable ex vivo functional profiling of radiotherapy-immunotherapy combinations.. BACKGROUND: Currently, radiotherapy-immunotherapy (RT-IO) combinations provide limited and heterogeneous benefits in human solid cancers and are frequently selected empirically, partly because human models that preserve native autologous tumor-immune interactions are lacking… |
Toxicology CRS | grade 4 |
Clinical OS | 16 |
Clinical Result source | ClinicalTrials.gov NCT00787761 |
Clinical Data Tier / Score | A · 36 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Autologous immune Cells (Autologous immune Cells) Liaoning Medical Diagnosis and Tre…·Lung Cancer (Locally Advanced or M… 31 trials |
|---|---|
Overview Program | Autologous immune Cells |
Overview Company | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. |
Overview Modality | CGT |
Overview Target | Lung Cancer (Locally Advanced or Metasta |
Overview Indication | Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | checkpoint co-expression score correlated with both overall and contact-dependent tumor cell death |
MoA Biomarker | biomarkers and therapeutic targets for investigating tumor-specific immune responses following locoregional t |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Autologous tumor-immune effusion cocultures enable ex vivo functional profiling of radiotherapy-immunotherapy combinations.. BACKGROUND: Currently, radiotherapy-immunotherapy (RT-IO) combinations provide limited and heterogeneous benefits in human solid cancers and are frequently selected empirically, partly because human models that preserve native autologous tumor-immune interactions are lacking… |
Toxicology CRS | grade 4 |
Clinical OS | 16 |
Clinical Result source | ClinicalTrials.gov NCT00787761 |
Clinical Data Tier / Score | A · 36 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교